Corvus Pharmaceuticals Stock Rallies 209% in a Month: Heres Why
CRVS stock surges 209% in a month after positive cohort 4 phase I data show durable eczema responses for soquelitinib.…
15,770€
-5,17%
Echtzeit-Aktienkurs Corvus Pharmaceuticals Inc.
Bid:
Ask:
Nachrichten zur Corvus Pharmaceuticals Inc. Aktie
Corvus Pharmaceuticals mit klinischem Durchbruch – Soquelitinib rückt ins Rampenlicht
Corvus Pharmaceuticals ist ein klinisch orientiertes Biopharmaunternehmen aus den USA, das neuartige Therapien zur Behandlung von Immun- und Krebserkrankungen entwickelt.…
Corvus Pharmaceuticals: ITK Inhibitor Soquelitinib AD Data Could Be Improved Upon
…
Corvus Pharmaceuticals, Inc. (CRVS) Discusses Phase 1 Clinical Trial Results of Soquelitinib in Atopic Dermatitis with Focus on Cohort 4 Transcript
…
Corvus Pharmaceuticals: Multiple Opportunities, But Plenty Of Risk
…
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2025 Earnings Call Transcript
…
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2024 Earnings Call Transcript
…
Corvus Pharmaceuticals: Not Just A One-Hit Wonder In ITK Inhibitor Targeting
…
Corvus Pharmaceuticals, Inc. (CRVS) Q3 2024 Earnings Call Transcript
…
Corvus Pharmaceuticals: Soquelitinibs High Stakes In PTCL Therapy
…
Corvus Pharmaceuticals, Inc. 2024 Q2 - Results - Earnings Call Presentation
…
Corvus Pharmaceuticals, Inc. (CRVS) Q2 2024 Earnings Call Transcript
…
Corvus Pharmaceuticals Is Ready To Take Flight
…
Corvus Pharmaceuticals, Inc. (CRVS) Q1 2024 Earnings Call Transcript
…
Corvus Pharmaceuticals, Inc. 2024 Q1 - Results - Earnings Call Presentation
…
Corvus Pharmaceuticals, Inc. (CRVS) Q4 2023 Earnings Call Transcript
…